BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+7.78%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$7.01B
AUM Growth
+$7.01B
(+1.7%)
Cap. Flow
-$225M
Cap. Flow
% of AUM
-3.21%
Top 10 Holdings %
Top 10 Hldgs %
36.63%
Holding
168
New
9
Increased
52
Reduced
52
Closed
12
Top Buys
| 1 |
Eli Lilly
LLY
|
$39.6M |
| 2 |
Evolent Health
EVH
|
$38.1M |
| 3 |
Merck
MRK
|
$34.6M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$27.1M |
| 5 |
Humana
HUM
|
$26.3M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$53.8M |
| 2 |
Sarepta Therapeutics
SRPT
|
$51.1M |
| 3 |
HCA Healthcare
HCA
|
$43.5M |
| 4 |
Intuitive Surgical
ISRG
|
$43.3M |
| 5 |
Boston Scientific
BSX
|
$42.1M |
Sector Composition
| 1 | Healthcare | 99.05% |
| 2 | Industrials | 0.87% |
| 3 | Energy | 0.03% |
| 4 | Communication Services | 0.01% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Becton Dickinson
BDX
$54.3B
| $89.2M | 1.27% |
337,723
-10,320
| -3% | -$2.72M |
|
27
Penumbra
PEN
$10.5B
| $80.6M | 1.15% |
234,220
-3,952
| -2% | -$1.36M |
|
|
SWAV
28
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $77.2M | 1.1% |
270,526
-10,850
| -4% | -$3.1M |
|
29
Option Care Health
OPCH
$4.7B
| $74.3M | 1.06% |
2,287,623
-154,562
| -6% | -$5.02M |
|
30
Insmed
INSM
$30.3B
| $69.6M | 0.99% |
3,300,911
+7,809
| +0.2% | +$165K |
|
31
Outset Medical
OM
$245M
| $68.4M | 0.98% |
3,125,886
+219,127
| +8% | +$4.79M |
|
32
Charles River Laboratories
CRL
$7.99B
| $66.1M | 0.94% |
314,513
+12,067
| +4% | +$2.54M |
|
33
Celldex Therapeutics
CLDX
$1.57B
| $61.1M | 0.87% |
1,800,000
| – | – |
|
|
ACCD
34
DELISTED
Accolade, Inc. Common Stock
ACCD
| $60.9M | 0.87% |
4,521,059
+479,258
| +12% | +$6.46M |
|
35
Align Technology
ALGN
$9.59B
| $60.5M | 0.86% |
171,140
| – | – |
|
36
Idexx Laboratories
IDXX
$50.7B
| $57.5M | 0.82% |
114,441
+3,513
| +3% | +$1.76M |
|
|
37
Humana
HUM
$37.5B
| $57M | 0.81% |
127,373
+58,803
| +86% | +$26.3M |
|
38
Veeva Systems
VEEV
$44.4B
| $53.6M | 0.76% |
271,046
+8,061
| +3% | +$1.59M |
|
39
Arvinas
ARVN
$580M
| $52.8M | 0.75% |
2,127,000
| – | – |
|
40
Relay Therapeutics
RLAY
$709M
| $52.4M | 0.75% |
4,170,800
-1,800
| -0% | -$22.6K |
|
41
Transmedics
TMDX
$3.65B
| $51.4M | 0.73% |
612,613
-16,871
| -3% | -$1.42M |
|
42
MacroGenics
MGNX
$121M
| $51.4M | 0.73% |
9,609,913
| – | – |
|
43
Tandem Diabetes Care
TNDM
$834M
| $51.4M | 0.73% |
2,092,934
+299,171
| +17% | +$7.34M |
|
44
Bio-Rad Laboratories Class A
BIO
$7.8B
| $51M | 0.73% |
134,533
+20,794
| +18% | +$7.88M |
|
45
CRISPR Therapeutics
CRSP
$4.82B
| $50.5M | 0.72% |
899,300
-500
| -0.1% | -$28.1K |
|
46
Thermo Fisher Scientific
TMO
$183B
| $50.1M | 0.72% |
96,101
+9,768
| +11% | +$5.1M |
|
47
Molina Healthcare
MOH
$9.6B
| $49.5M | 0.71% |
164,338
+21,729
| +15% | +$6.55M |
|
|
48
HCA Healthcare
HCA
$95.4B
| $48.7M | 0.69% |
160,515
-143,271
| -47% | -$43.5M |
|
49
Exelixis
EXEL
$9.95B
| $48.4M | 0.69% |
2,534,000
-75,000
| -3% | -$1.43M |
|
|
50
Apellis Pharmaceuticals
APLS
$3.51B
| $47.2M | 0.67% |
518,495
-590,887
| -53% | -$53.8M |
|